Alzheimer’s is one of the most prevalent brain diseases in the world. 26 million people worldwide suffer from Alzheimer’s disease (AD), which kills more people than breast and prostate cancer combined. The economic toll is staggering. By 2030, it will cost Europe €250 billion to care for people with dementia. Moreover, 72 million baby boomers will reach the age of risk by 2030, and by 2050, total healthcare cost of AD is estimated to top $1.1 trillion.
Since the year 2000, the death rate of AD has increased by 71%, but even today, only 45% of people with AD are properly diagnosed, normally by a primary care physician. There is no single, simple test to diagnose AD because of the specific challenges it poses to researchers. A slow recruitment period for patients and symptoms that emerge a decade after the disease starts make clinical trials expensive, lengthy and logistically complicated.
Our platform provides support for researchers of AD by identifying characteristic patterns (e.g. with Volumetry analysis) of structural and functional cerebral alterations. Imaging is central to identifying vascular and non-AD degenerative pathologies and has helped in the recognition of the prevalence of mixed pathologies in dementia.